Ann De Smedt

Ann De Smedt

Auto-generated profile, based on publicly available information

Ann De Smedt

STIMULUS Research Group, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2022 in JMIR Serious Games
Verified
Journal Article
Open access
Lisa GoudmanLisa Goudman
Lisa Goudman
JJJulie Jansen
Julie Jansen
Maxime BillotMaxime Billot
Maxime Billot
NVNieke Vets
Nieke Vets
ASAnn De Smedt
Ann De Smedt
MMMaarten Moens
Maarten Moens
Background: Virtual reality (VR) is a computer technology that immerses a user in a completely different reality. The application of VR in acute pain settings is well established. However, in chronic pain, the applications and outcome parameters influenced by VR are less clear.Objective: This review aimed to systematically identify all outcome parameters that are reported in relation to VR in patients with chronic pain.Methods: A total of 4 electronic databases (PubMed, Scopus, Web of Science, and Embase) were searched for relevant studies. Multilevel random-effect meta-analyses were performed, whereby the standardized mean difference was chosen as the effect size to denote the difference between measurements before and after a VR intervention.Results: The initial database search identified 1430 studies, of which 41 (2.87%) were eventually included in the systematic review. Evidence has been found for the effects of VR on pain, functioning, mobility, functional capacity, psychological outcomes, quality of life, neuropsychological outcomes, and physical sensations. The overall effect size (a total of 194 effect sizes from 25 studies) based on a three level meta-analysis was estimated at 1.22 (95% CI 0.55-1.89; z=3.56; P<.001), in favor of improvements after a VR intervention. When categorizing effect sizes, the overall effect sizes were reported as follows: 1.60 (95% CI 0.83-2.36; z=4.09; P<.001) for the effect of VR on pain (n=31), 1.40 (95% CI 0.13-2.67; z=2.17; P=.03) for functioning (n=60), 0.49 (95% CI −0.71 to 1.68; z=0.80; P=.42) for mobility (n=24), and 0.34 (95% CI −1.52 to 2.20; z=0.36; P=.72) for functional capacity (n=21).Conclusions: This systematic review revealed a broad range of outcome variables influenced by an intervention of VR technology, with statistically significant pain relief and improvements in functioning. These findings indicate that VR not only has applications in acute pain management but also in chronic pain settings, whereby VR might be able to become a promising first-line intervention as complementary therapy for patients with chronic pain.Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42021227016; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=227016

1 April 2000 in Food Research International
Verified
Journal Article
Closed access
DDD Demeyer
D Demeyer
MRM Raemaekers
M Raemaekers
ARA Rizzo
A Rizzo
AHA Holck
A Holck
ASA De Smedt
A De Smedt
SES Eerola
S Eerola

23 July 2015 in International Journal of Stroke
Verified
Journal Article
Closed access
LYLaetitia Yperzeele
Laetitia Yperzeele
RHRobbert-Jan van Hooff
Robbert-Jan van Hooff
GNGuy Nagels
Guy Nagels
ASAnn De Smedt
Ann De Smedt
JKJacques De Keyser
Jacques De Keyser
RBRaf Brouns
Raf Brouns

21 March 2016 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
JBJoão Barroso
João Barroso
UPUwe Pfannenbecker
Uwe Pfannenbecker
EAEls Adriaens
Els Adriaens
NANathalie Alépée
Nathalie Alépée
MCMagalie Cluzel
Magalie Cluzel
PMPauline McNamee
Pauline McNamee
A thorough understanding of which of the effects assessed in the in vivo Draize eye test are responsible for driving UN GHS/EU CLP classification is critical for an adequate selection of chemicals to be used in the development and/or evaluation of alternative methods/strategies and for properly assessing their predictive capacity and limitations. For this reason, Cosmetics Europe has compiled a database of Draize data (Draize eye test Reference Database, DRD) from external lists that were created to support past validation activities. This database contains 681 independent in vivo studies on 634 individual chemicals representing a wide range of chemical classes. A description of all the ocular effects observed in vivo, i.e. degree of severity and persistence of corneal opacity (CO), iritis, and/or conjunctiva effects, was added for each individual study in the database, and the studies were categorised according to their UN GHS/EU CLP classification and the main effect driving the classification. An evaluation of the various in vivo drivers of classification compiled in the database was performed to establish which of these are most important from a regulatory point of view. These analyses established that the most important drivers for Cat 1 Classification are (1) CO mean ≥ 3 (days 1–3) (severity) and (2) CO persistence on day 21 in the absence of severity, and those for Cat 2 classification are (3) CO mean ≥ 1 and (4) conjunctival redness mean ≥ 2. Moreover, it is shown that all classifiable effects (including persistence and CO = 4) should be present in ≥60 % of the animals to drive a classification. As a consequence, our analyses suggest the need for a critical revision of the UN GHS/EU CLP decision criteria for the Cat 1 classification of chemicals. Finally, a number of key criteria are identified that should be taken into consideration when selecting reference chemicals for the development, evaluation and/or validation of alternative methods and/or strategies for serious eye damage/eye irritation testing. Most important, the DRD is an invaluable tool for any future activity involving the selection of reference chemicals.

2 September 2012 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
MMMaarten Moens
Maarten Moens
SSS. Sunaert
S. Sunaert
PMP. Mariën
P. Mariën
RBR. Brouns
R. Brouns
ASA. De Smedt
A. De Smedt
BNB. Nuttin
B. Nuttin

24 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LYLaetitia Yperzeele
Laetitia Yperzeele
RHRobbert-Jan Van Hooff
Robbert-Jan Van Hooff
ASAnn De Smedt
Ann De Smedt
AEAlexis Valenzuela Espinoza
Alexis Valenzuela Espinoza
RDRita Van Dyck
Rita Van Dyck
RBRaf Brouns
Raf Brouns
Telemedicine is currently mainly applied as an in-hospital service, but this technology also holds potential to improve emergency care in the prehospital arena. We report on the safety, feasibility and reliability of in-ambulance teleconsultation using a telemedicine system of the third generation. A routine ambulance was equipped with a system for real-time bidirectional audio-video communication, automated transmission of vital parameters, glycemia and electronic patient identification. All patients ( ≥18 years) transported during emergency missions by a Prehospital Intervention Team of the Universitair Ziekenhuis Brussel were eligible for inclusion. To guarantee mobility and to facilitate 24/7 availability, the teleconsultants used lightweight laptop computers to access a dedicated telemedicine platform, which also provided functionalities for neurological assessment, electronic reporting and prehospital notification of the in-hospital team. Key registrations included any safety issue, mobile connectivity, communication of patient information, audiovisual quality, user-friendliness and accuracy of the prehospital diagnosis. Prehospital teleconsultation was obtained in 41 out of 43 cases (95.3%). The success rates for communication of blood pressure, heart rate, blood oxygen saturation, glycemia, and electronic patient identification were 78.7%, 84.8%, 80.6%, 64.0%, and 84.2%. A preliminary prehospital diagnosis was formulated in 90.2%, with satisfactory agreement with final in-hospital diagnoses. Communication of a prehospital report to the in-hospital team was successful in 94.7% and prenotification of the in-hospital team via SMS in 90.2%. Failures resulted mainly from limited mobile connectivity and to a lesser extent from software, hardware or human error. The user acceptance was high. Ambulance-based telemedicine of the third generation is safe, feasible and reliable but further research and development, especially with regard to high speed broadband access, is needed before this approach can be implemented in daily practice.